Recently, Cencora’s Reimbursement and Policy Insights team partnered with fellow expert Jennifer Snow and the Medicare Access for Patients Rx (MAPRx) coalition to publish a white paper focused on the Inflation Reduction Act’s unintended consequences. You can access the white paper here: https://lnkd.in/ePGhZMkA While IRA’s Part D benefit redesign will alleviate affordability challenges for many Part D beneficiaries, the law could have significant downstream impacts for patient access within the benefit. In the paper, we explore the following potential access challenges for Part D beneficiaries. · Increase in Part D monthly plan premiums · Narrower formulary coverage · Increase in utilization management · Reduced standalone prescription drug plan availability Given these impacts, Part D beneficiaries may face greater access challenges despite the ease in their overall out-of-pocket (OOP) cost burden, necessitating patient organizations and patient support programs to be nimble in their approach for how they are supporting patients into next year. As we learn more learn more about how the Part D market is changing in 2025 over the coming weeks, Cencora’s consulting team is here to offer our insights on the impact to market and patient access.
This is a great overview and illustrative of how policy changes will impact managed care orgs and market access. Thanks for sharing, Corey Ford and Jennifer Snow!
Very informative
NPC Chief Strategy Officer | Kimpossibility Coaching, Retreats, & Yoga | Biopharmaceutical & Health Policy Researcher | Public Speaker
6moUnintended consequences abound! Here are some additional resources from National Pharmaceutical Council research: https://www.npcnow.org/sites/default/files/2024-04/NPC%20and%20the%20IRA%20One%20Pager%20April%202024_0.pdf